You are here: Industry Insights > Market News > Financial Report: PPD

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Financial Report: PPD

contractpharmaOctober 30, 2020

Tag: PPD , Financial Report , revenues

Favorites

PPD

3Q Revenues: $1.2 billion (+21%)

3Q Earnings: $9.1 million (-45%)

YTD Revenues: $3.3 billion (+11%)

YTD Earnings: $58.1 million (+69%)

Comments: Clinical Development Services revenue was $1.0 billion in the quarter, up 19% and Laboratory Services revenue was $225.2 million, up 27%. Net authorizations of $1.2 billion, representing 33% growth over third quarter 2019 and resulting in a net book-to-bill ratio of 1.35x on a historical basis. Ending backlog of $7.9 billion, representing 16% growth over third quarter 2019.

Previous:TherapeutAix Expands R&D Network

Next:Avomeen Names SVP of Lab Operations

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

The life science group Sartorius is collaborating with biopharmaceutical company Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing.

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

Financial Report: PPD | Pharmasources.com

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

Biotech NewswireMay 09, 2024

MetP Pharma AG, leveraging the proprietary nose-to-brain drug delivery technology BrainDos™ in internal and external product development and manufacturing programs.

Financial Report: PPD

Related News

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

You may like